Free Trial
OTCMKTS:NVZMY

Novozymes A/S Q1 2026 Earnings Results & Report

Novozymes A/S logo
$68.13 -0.46 (-0.67%)
As of 02:44 PM Eastern

Novozymes A/S missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 5, 2026. The company reported EPS of $0.51 versus the $0.8160 consensus estimate, while revenue of $1.31 billion fell short of the $1.32 billion estimate by $13.17 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Novozymes A/S EPS Results

Actual EPS
$0.51
Consensus EPS
$0.8160
Beat/Miss
Missed by -$0.3060
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

Novozymes A/S Revenue Results

Actual Revenue
$1.31 billion
Expected Revenue
$1.32 billion
Beat/Miss
Missed by -$13.17 million
YoY Revenue Growth
N/A

Upcoming Earnings

Novozymes A/S' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules.

Conference Call Resources

Novozymes A/S Q1 2026 Earnings FAQ

Novozymes A/S (OTCMKTS:NVZMY) reported earnings of $0.51 per share for Q1 2026, missing the consensus estimate of $0.8160. The report was announced on Tuesday, May 5, 2026.

Novozymes A/S reported revenue of $1.31 billion for Q1 2026, against a consensus estimate of $1.32 billion.

Novozymes A/S' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Novozymes A/S on the company's earnings history page.

Novozymes A/S Earnings Headlines

Novozymes A/S (NVZMY) Q2 2026 Earnings Call Transcript
The oil check Munger called his best deal
Charlie Munger's $1,000 oil investment in 1962 later paid about $70,000 a year, totaling roughly $1 million over 60 years, according to his own account. Today, a similar oil income opportunity trades under $15 per unit, offering exposure to more than 17 million gross acres across 28 states and over 137,000 producing wells. It has paid a distribution every quarter since its 2017 IPO, including through the 2020 oil crash.tc pixel
Novonesis (Novozymes) B ADR NVZMY
Novozymes AS DRC (NVZMY)
See More Novozymes A/S Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novozymes A/S? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novozymes A/S and other key companies, straight to your email.

About Novozymes A/S

Novozymes A/S (OTCMKTS:NVZMY) was a Danish biotechnology company specializing in biological solutions based on enzymes, microorganisms and related technologies. Its products were designed to help businesses improve manufacturing efficiency, reduce resource use and develop more sustainable alternatives to conventional chemical processes.

The company supplied enzyme and microbial products for a range of industries, including household care, food and beverages, agriculture, animal health, bioenergy and industrial manufacturing. Applications included laundry and cleaning products, baking and brewing, starch processing, animal feed, crop-related solutions and the production of biofuels and other biobased materials.

Novozymes was established as an independent company in 2000 after being separated from Novo Nordisk and served customers across global markets through research, production and commercial operations in multiple regions. In January 2024, Novozymes combined with Chr. Hansen, another Danish bioscience company, to form Novonesis. Ester Baiget served as Novozymes’ president and chief executive officer before and during the combination process.

View Novozymes A/S Profile